Navigation Links
Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
Date:3/2/2010

PITTSBURGH, March 2 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2009, as filed with the U.S. Securities and Exchange Commission on Feb. 26, 2010, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724-514-1813.

This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Back to top

RELATED LINKS
http://www.mylan.com

'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
2. Mylan Parts Ways with Chief Financial Officer Jolene Varney
3. Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
4. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
7. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
8. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
9. Mylan Announces Enhancements to Executive Management Team
10. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
11. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of ... manage stress and anxiety. , “Buzzies change the way we interact with stress ... Buzzies. , Since its launch date in December 2016, The TouchPoint Solution has sold ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... management and workflow solutions, today named The Resource Group as their 2016 Microsoft ... and partner conference in Newport Beach, CA. The award recognizes The Resource ...
(Date:3/23/2017)... ... 23, 2017 , ... According to the National Sleep Foundation , poor ... the only cause of the sunken-eye look, which can include dark circles or bags ... poor health are likely due to genetics, dehydration, allergies, and losing fat beneath the ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys through ... sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted to ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017   Icertis , the leading ... the cloud, today announced an upgrade to the ... to improve clinical trials contract management. Built on ... the solution speeds up clinical trial contracting while ... (CRO). "The pharmaceutical industry is ...
(Date:3/23/2017)... 23, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: ... integrated commercial company that provides clinically useful molecular ... it has entered into agreements to successfully restructure ... ("RedPath") and concurrently terminate its royalty and milestone ... debt to RedPath amounting to $9.34 million is ...
(Date:3/23/2017)... 2017  Additive Orthopaedics, LLC., an early stage ... kicked off a multi-centered clinical study to measure ... According to Brian McLaughlin , ... structures have already shown tremendous post-operative success and ... wedges from which we have seen evidence of ...
Breaking Medicine Technology: